AditxtScore™ for COVID-19+file for EUA+commercially available Q1

Aditxt Introduces AditxtScore™ for COVID-19 and Announces the Completion of Validation Studies by Stanford Blood Center

AditxtScore™ for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens

Aditxt plans to file for an Emergency Use Authorization (EUA) followed by a 510(K) application with the U.S. Food and Drug Administration by the end of the current quarter (Q3, 2020).

Additionally, Aditxt is planning its operational capabilities in anticipation of beginning pilot programs utilizing AditxtScore™ for COVID-19 in Q4, 2020, with the goal of making AditxtScore™ commercially available starting in Q1, 2021.

finance.yahoo.com/news/aditxt-introduces-aditxtscore-covid-19-120000862.html?guce_referrer=aHR0cHM6Ly9maW52aXouY29tL3F1b3RlLmFzaHg_dD1BRFRYJnR5PWMmcD1kJmI9MQ&guce_referrer_sig=AQAAACikHVvS8-hGnPsTNgYnMzqpJCf9wNNteEpn3akLpPYWRBhfwD6TL1Y9dpjE6jAD5e2x1h9Oturcn3SIrluCfdzDR59tmBgoF3kjOPfQBhsdhRR77DHI3feh8k54XhytdhNlAp1AQwhM7Q4_-C0pdQ-9WoHHyTvrsx29ohL3B5_9&_guc_consent_skip=1596794102